Biomedicine & Pharmacotherapy,
Год журнала:
2024,
Номер
179, С. 117344 - 117344
Опубликована: Авг. 27, 2024
Osteoarthritis
(OA)
is
the
most
common
degenerative
joint
disease.
Multiple
tissues
are
altered
during
development
of
OA,
resulting
in
pain
and
permanent
damage
to
osteoarticular
joints.
Current
research
has
demonstrated
that
non-apoptotic
cell
death
plays
a
crucial
role
OA.
With
continuous
targeted
therapies,
shown
great
potential
prevention
treatment
We
systematically
reviewed
progress
on
pathogenesis,
development,
outcome
including
autophagy,
pyroptosis,
ferroptosis,
necroptosis,
immunogenic
death,
parthanatos.
This
article
reviews
mechanism
OA
provides
theoretical
basis
for
identification
new
targets
treatment.
ACS Medicinal Chemistry Letters,
Год журнала:
2024,
Номер
15(2), С. 177 - 178
Опубликована: Янв. 26, 2024
Provided
herein
are
novel
fused
triazole
compounds
as
RIPK1
inhibitors,
pharmaceutical
compositions,
use
of
such
in
treating
neurodegenerative,
autoimmune,
and
inflammatory
diseases,
processes
for
preparing
compounds.
Archiv der Pharmazie,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 21, 2024
Necroptosis
is
a
regulated
inflammatory
cell
death
process
that
closely
associated
with
autoimmune
diseases,
acute
ischemic
injuries,
neurodegenerative
disorders,
and
so
on.
Due
to
the
crucial
role
of
receptor-interacting
protein
kinase
1
(RIPK1)
in
necroptosis
pathway,
RIPK1
inhibitors
are
believed
have
great
potential
treatment
necroptosis-related
diseases.
In
this
article,
we
reported
series
pyridazin-4-one
derivatives
as
potent
for
both
human
mouse
cells.
The
representative
compound
13
exhibited
favorable
selectivity
dose-dependently
inhibited
phosphorylation.
vivo
pharmacokinetic
study
indicated
was
an
orally
available
candidate.
Finally,
molecular
docking
dynamics
simulations
were
performed
elucidate
binding
pattern
RIPK1.
Collectively,
represents
promising
lead
future
development
RIPK1-targeted
inhibitors.
